Bromazolam Powder
Bromazolam Powder for Sale Online | Purchase Bromazolam Powder
Introduction to Bromazolam
Bromazolam Powder, also known by its chemical designation XLI-268, is a triazolobenzodiazepine (TBZD) that was originally synthesized in 1976 but was never commercially available. The substance has subsequently emerged as a designer drug, with its presence first officially recorded by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in Sweden in 2016. Bromazolam is chemically related to alprazolam, differing only by the substitution of a bromine atom in place of the chlorine atom found in alprazolam. It exhibits similar sedative and anxiolytic (anxiety-reducing) effects as other benzodiazepines.
Pharmacological Profile
Bromazolam acts as a nonsubtype selective agonist at the benzodiazepine site of GABAA receptors. It demonstrates notable binding affinities: 2.81 nM at the ?1 subtype, 0.69 nM at the ?2 subtype, and 0.62 nM at the ?5 subtype.
Clinical Uses of Bromazolam Powder
- Short-Term Treatment of Insomnia: Bromazolam is often used for short-term management of sleep disorders.
- Management of Anxiety Disorders: It is prescribed for anxiety conditions such as obsessive-compulsive disorder (OCD) and generalized anxiety disorder (GAD), mainly as a short-term solution and used on an as-needed basis.
Adverse Effects
- Long-Term Use Risks: Chronic use of Bromazolam may lead to blepharospasms (involuntary eye twitching), particularly in women. Doses of 4 mg or more might cause anterograde amnesia (difficulty forming new memories).
- Rare Skin Reactions: In rare instances, users may experience erythema annular centrifugum (ring-shaped skin lesions).
Tolerance, Dependence, and Withdrawal
Abrupt discontinuation of Bromazolam, similar to other benzodiazepines, can lead to withdrawal symptoms, including rebound insomnia. Bromazolam has a shorter half-life compared to benzodiazepines like diazepam, leading to more rapid declines in blood plasma levels and potentially exacerbating withdrawal effects.
In clinical studies comparing Bromazolam with other benzodiazepines like etizolam and alprazolam for generalized anxiety disorders, all three drugs were effective over two weeks. Bromazolam showed increasing efficacy from two weeks to four weeks. A regimen of 0.5 grams of Bromazolam administered twice daily did not result in significant cognitive deficits over three weeks compared to a placebo.
Research involving animal models demonstrated that Bromazolam induces less tolerance and dependence compared to traditional benzodiazepines. For instance, lorazepam led to downregulation of ?1 benzodiazepine binding sites, contributing to tolerance and dependence, whereas Bromazolam showed reduced propensity for such issues. Similarly, etizolam increased ?2 benzodiazepine binding sites, potentially countering tolerance to anti-anxiety effects. Bromazolam thus appears to be a promising anxiolytic with a lower risk of tolerance and dependence.
Overdose Risks
Bromazolam has been associated with overdose cases, particularly when combined with other GABAergic substances. Despite its lower LD50 compared to some benzodiazepines, Bromazolam’s LD50 is still significantly higher than typical therapeutic doses.
Flumazenil, a GABA antagonist used to reverse benzodiazepine overdoses, can counteract the effects of Bromazolam as well as other traditional benzodiazepines.
Reports indicate a rise in Bromazolam-related overdose deaths. For example, the National Records of Scotland reported that ‘street’ Bromazolam was linked to 752 drug-related fatalities (59%) in Scotland in 2019. It is important to note that most of these fatalities involved multiple substances, with opioids and opiates contributing to 86% of drug-related deaths.
Safety and Purchasing
When purchasing Bromazolam powder online, ensure that you obtain it from a reputable source to avoid counterfeit products and reduce risks associated with misuse. Always follow medical guidance and be aware of the potential risks and side effects associated with its use.
